» Articles » PMID: 29991556

Single-cell Approaches Identify the Molecular Network Driving Malignant Hematopoietic Stem Cell Self-renewal

Abstract

Recent advances in single-cell technologies have permitted the investigation of heterogeneous cell populations at previously unattainable resolution. Here we apply such approaches to resolve the molecular mechanisms driving disease in mouse hematopoietic stem cells (HSCs), using JAK2V617F mutant myeloproliferative neoplasms (MPNs) as a model. Single-cell gene expression and functional assays identified a subset of JAK2V617F mutant HSCs that display defective self-renewal. This defect is rescued at the single HSC level by crossing JAK2V617F mice with mice lacking TET2, the most commonly comutated gene in patients with MPN. Single-cell gene expression profiling of JAK2V617F-mutant HSCs revealed a loss of specific regulator genes, some of which were restored to normal levels in single TET2/JAK2 mutant HSCs. Of these, and, to a lesser extent, and overexpression in JAK2-mutant HSCs could drive a disease phenotype and retain durable stem cell self-renewal in functional assays. Together, these single-cell approaches refine the molecules involved in clonal expansion of MPNs and have broad implications for deconstructing the molecular network of normal and malignant stem cells.

Citing Articles

Tyrosine phosphorylation of CARM1 promotes its enzymatic activity and alters its target specificity.

Itonaga H, Mookhtiar A, Greenblatt S, Liu F, Martinez C, Bilbao D Nat Commun. 2024; 15(1):3415.

PMID: 38649367 PMC: 11035800. DOI: 10.1038/s41467-024-47689-4.


PBX1: a TALE of two seasons-key roles during development and in cancer.

Crisafulli L, Brindisi M, Liturri M, Sobacchi C, Ficara F Front Cell Dev Biol. 2024; 12:1372873.

PMID: 38404687 PMC: 10884236. DOI: 10.3389/fcell.2024.1372873.


Single-cell Technology in Stem Cell Research.

Golchin A, Shams F, Moradi F, Sadrabadi A, Parviz S, Alipour S Curr Stem Cell Res Ther. 2024; 20(1):9-32.

PMID: 38243989 DOI: 10.2174/011574888X265479231127065541.


Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.

Dunbar A, Bowman R, Park Y, OConnor K, Izzo F, Myers R Cancer Discov. 2024; 14(5):737-751.

PMID: 38230747 PMC: 11061606. DOI: 10.1158/2159-8290.CD-22-0952.


Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer.

Zeng Z, Fu M, Hu Y, Wei Y, Wei X, Luo M Mol Cancer. 2023; 22(1):172.

PMID: 37853437 PMC: 10583419. DOI: 10.1186/s12943-023-01877-w.


References
1.
Ortmann C, Kent D, Nangalia J, Silber Y, Wedge D, Grinfeld J . Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015; 372(7):601-612. PMC: 4660033. DOI: 10.1056/NEJMoa1412098. View

2.
Dykstra B, Olthof S, Schreuder J, Ritsema M, de Haan G . Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells. J Exp Med. 2011; 208(13):2691-703. PMC: 3244040. DOI: 10.1084/jem.20111490. View

3.
Mohty M, Yong A, Szydlo R, Apperley J, Melo J . The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood. 2007; 110(1):380-3. DOI: 10.1182/blood-2006-12-065599. View

4.
Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023. View

5.
Bryder D, Rossi D, Weissman I . Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am J Pathol. 2006; 169(2):338-46. PMC: 1698791. DOI: 10.2353/ajpath.2006.060312. View